EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Inhibition of Macrophage-Specific CHIT1 as an Approach to Treat Airway Remodeling in Severe Asthma

Piotr Sklepkiewicz iD, Barbara Dymek, Michal Mlacki iD, Agnieszka Zagozdzon iD, Magdalena Salamon, Anna Maria Siwińska, Marcin Piotr Mazurkiewicz, Natalia de Souza Xavier Costa iD, Marzena Mazur iD, Thais Mauad iD, Adam Gołębiowski, Karolina Dzwonek und 2 weitere

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24054719 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Piotr Sklepkiewicz und 13 weiteren Autor:innen. Beteiligte Einrichtung: Molecure SA, 02-089 Warsaw, Poland. Hauptthemen laut MEDLINE: Airway Remodeling, Asthma, Chitinases, Protein Kinase Inhibitors. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Preclinical research and clinical trials of a first-in-class development candidate in the therapy of asthma and inflammatory bowel disease (IBD), Development of a 'first-in-class' small molecule drug candidate for treatment of idiopathic pul-monary fibrosis through chitotriosidase inhibition (IPF), Development of a ‘first-in-class’ small molecule drug candidate for treatment of idiopathic pul-monary fibrosis through chitotriosidase inhibition (IPF).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chitotriosidase (CHIT1) is an enzyme produced by macrophages that regulates their differentiation and polarization. Lung macrophages have been implicated in asthma development; therefore, we asked whether pharmacological inhibition of macrophage-specific CHIT1 would have beneficial effects in asthma, as it has been shown previously in other lung disorders. CHIT1 expression was evaluated in the lung tissues of deceased individuals with severe, uncontrolled, steroid-naïve asthma. OATD-01, a chitinase inhibitor, was tested in a 7-week-long house dust mite (HDM) murine model of chronic asthma characterized by accumulation of CHIT1-expressing macrophages. CHIT1 is a dominant chitinase activated in fibrotic areas of the lungs of individuals with fatal asthma. OATD-01 given in a therapeutic treatment regimen inhibited both inflammatory and airway remodeling features of asthma in the HDM model. These changes were accompanied by a significant and dose-dependent decrease in chitinolytic activity in BAL fluid and plasma, confirming in vivo target engagement. Both IL-13 expression and TGFβ1 levels in BAL fluid were decreased and a significant reduction in subepithelial airway fibrosis and airway wall thickness was observed. These results suggest that pharmacological chitinase inhibition offers protection against the development of fibrotic airway remodeling in severe asthma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Airway RemodelingAsthmaChitinasesProtein Kinase InhibitorsAnimalsHumansMiceDisease Models, AnimalLungMacrophagesPyroglyphidaeHexosaminidasesPiperidinesTriazoles

Stichwörter der Autor:innen

asthmachitotriosidasemacrophage

Substanzen

ChitinasesProtein Kinase InhibitorschitotriosidaseHexosaminidasesOATD-01PiperidinesTriazoles

Autor:innen und Institutionen

  • Molecure SA, 02-089 Warsaw, Poland.
  • Department of Pathology, Faculty of Medicine, University of São Paulo, Avenida Dr. Arnaldo, 455, Room 1150, Cerqueira Cesar, São Paulo 01246-903, Brazil.
  • Department of Immunology, Medical University of Warsaw, 02-097 Warsaw, Poland.

ORCID-Profile: Piotr Sklepkiewicz, Michal Mlacki, Agnieszka Zagozdzon, Natalia de Souza Xavier Costa, Marzena Mazur, Thais Mauad, Jakub Gołąb

Förderung

  • Preclinical research and clinical trials of a first-in-class development candidate in the therapy of asthma and inflammatory bowel disease (IBD)
  • Development of a 'first-in-class' small molecule drug candidate for treatment of idiopathic pul-monary fibrosis through chitotriosidase inhibition (IPF)
  • Development of a ‘first-in-class’ small molecule drug candidate for treatment of idiopathic pul-monary fibrosis through chitotriosidase inhibition (IPF)

Zitieren

APA

Sklepkiewicz, P., Dymek, B., Mlacki, M., Zagozdzon, A., Salamon, M., Siwińska, A. M., Mazurkiewicz, M. P., de Souza Xavier Costa, N., Mazur, M., Mauad, T., Gołębiowski, A., Dzwonek, K., Gołąb, J., & Zasłona, Z. (2023). Inhibition of Macrophage-Specific CHIT1 as an Approach to Treat Airway Remodeling in Severe Asthma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24054719

Vancouver

Sklepkiewicz P, Dymek B, Mlacki M, Zagozdzon A, Salamon M, Siwińska AM, et al. Inhibition of Macrophage-Specific CHIT1 as an Approach to Treat Airway Remodeling in Severe Asthma. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24054719

BibTeX
@article{Sklepkiewicz2023,
  author = {Sklepkiewicz, Piotr and Dymek, Barbara and Mlacki, Michal and Zagozdzon, Agnieszka and Salamon, Magdalena and Siwińska, Anna Maria and Mazurkiewicz, Marcin Piotr and de Souza Xavier Costa, Natalia and Mazur, Marzena and Mauad, Thais and Gołębiowski, Adam and Dzwonek, Karolina and Gołąb, Jakub and Zasłona, Zbigniew},
  title = {Inhibition of Macrophage-Specific CHIT1 as an Approach to Treat Airway Remodeling in Severe Asthma},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24054719}
}
Kostenlos starten →